More than 700,000 older Americans have started taking GLP-1 medications since Medicare began covering the drug class in July, according to Eli Lilly’s chief executive, marking one of the most significant expansions of access to the weight-loss and diabetes treatments since they entered the US market. The figure, disclosed by the company’s top executive, illustrates how quickly demand has grown once the federal health insurance programme for seniors opened the door to coverage that was previously limited largely to those with private insurance or the means to pay out of pocket.
Of those new patients, roughly 70 percent are taking Eli Lilly products, a share that points to the Indiana-based drugmaker’s strong position in a rapidly expanding segment of the pharmaceutical market. The company’s Mounjaro and Zepbound treatments have become widely prescribed options for diabetes management and weight loss, and the Medicare data suggest they are now also the preferred choice among newly eligible seniors. The remaining share of new patients are understood to be using rival products from Novo Nordisk, whose Ozempic and Wegovy brands have similarly become household names amid the global surge in interest in GLP-1 therapies.
Competitive stakes and global context
The figures, first reported by Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs, highlight the intensifying rivalry between the two dominant players in the obesity and diabetes drug market. Both companies have invested heavily in expanding manufacturing capacity to meet demand that has, at times, outstripped supply. Eli Lilly’s apparent lead among new Medicare users could reflect a combination of factors, including production capacity, physician prescribing habits and brand recognition built up over recent years as GLP-1 drugs moved from niche diabetes treatments to mainstream weight-management therapies.
The scale of uptake also underscores the broader shift underway in the pharmaceutical industry, an area of the business world that has drawn heightened investor attention as GLP-1 drugs have become one of the fastest-growing and most profitable categories in modern medicine. Analysts have pointed to the class of drugs as a major driver of revenue growth for both Eli Lilly and Novo Nordisk in recent years, with Medicare’s decision to extend coverage expected to further accelerate sales in the world’s largest healthcare market.
For Gulf audiences, the development carries indirect but notable relevance. Obesity and diabetes rates across the GCC are among the highest globally, and interest in GLP-1 treatments has grown accordingly among patients and healthcare providers in the region. However, unlike the newly expanded Medicare coverage in the United States, GLP-1 medications remain largely inaccessible through public healthcare systems across the Gulf, leaving many patients reliant on private insurance or direct payment. As US policy shifts continue to reshape global demand and pricing dynamics for these drugs, regional health systems and insurers may face growing pressure to reassess coverage policies, particularly as manufacturers expand production and seek to broaden access in international markets beyond North America.
